Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Levi Strauss & Co. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.54 (market cap $29.60B), while Levi Strauss & Co. trades at $22.54 (market cap $8.75B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.4× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.81% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LEVI | |
|---|---|---|
Market Cap | $29.60B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $25.53 |
52-Week Low | $205.48 | $17.92 |
Enterprise Value | $27.56B | $10.07B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Levi Strauss (LEVI) trades at $22.57, down 4.32% amid a recent cybersecurity breach disclosure. The stock maintains strong fundamentals with a 9.66% net margin and 29.31% ROE, supported by three consecutive quarterly earnings beats. Technical indicators show mixed signals with bearish moving averages but oversold RSI conditions. Analyst consensus remains strongly bullish with a $27.88 price target representing 23.5% upside potential.
Despite near-term cybersecurity concerns, Levi's demonstrates robust DTC growth and digital transformation success. The company's raised 2026 outlook and dividend increase signal confidence, though execution risks and tariff pressures warrant monitoring. Current valuation at 16.24 P/E offers reasonable entry for long-term investors seeking exposure to the iconic brand's turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
